1. Home
  2. EMN vs BLCO Comparison

EMN vs BLCO Comparison

Compare EMN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Chemical Company

EMN

Eastman Chemical Company

HOLD

Current Price

$78.44

Market Cap

7.1B

Sector

Industrials

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.97

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMN
BLCO
Founded
1920
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
5.9B
IPO Year
1993
2022

Fundamental Metrics

Financial Performance
Metric
EMN
BLCO
Price
$78.44
$16.97
Analyst Decision
Buy
Hold
Analyst Count
14
13
Target Price
$78.21
$17.25
AVG Volume (30 Days)
1.9M
320.4K
Earning Date
01-29-2026
02-18-2026
Dividend Yield
4.34%
N/A
EPS Growth
N/A
N/A
EPS
4.10
N/A
Revenue
$8,752,000,000.00
$4,976,000,000.00
Revenue This Year
$1.78
$8.06
Revenue Next Year
$3.35
$5.81
P/E Ratio
$18.89
N/A
Revenue Growth
N/A
6.23
52 Week Low
$56.11
$10.45
52 Week High
$103.82
$17.86

Technical Indicators

Market Signals
Indicator
EMN
BLCO
Relative Strength Index (RSI) 73.38 52.73
Support Level $75.08 $16.17
Resistance Level $79.31 $17.13
Average True Range (ATR) 2.54 0.43
MACD 0.82 -0.03
Stochastic Oscillator 94.15 60.58

Price Performance

Historical Comparison
EMN
BLCO

About EMN Eastman Chemical Company

Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: